Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

about

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

Item

http://www.wikidata.org/entity/Q48098307

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@en

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@nl

type

Item

label

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@en

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@nl

prefLabel

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@en

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@nl

P1476

Alternate dosing regimens of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma.

@en

P2093

Y H Kim

http://www.w3.org/2001/XMLSchema#string

P2860

The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.

Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.

Brentuximab vedotin: axonal microtubule's Apollyon.

Brentuximab Vedotin for Patients With Refractory Lymphomatoid Papulosis: An Analysis of Phase 2 Results.

Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients.

P304

302-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.15970

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

178

http://www.w3.org/2001/XMLSchema#string

P50

D J Lewis

M Duvic

P577

2017-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28889405

http://www.w3.org/2001/XMLSchema#string